These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 33684397)

  • 41. Optimization Rules for SARS-CoV-2 M
    Stoddard SV; Stoddard SD; Oelkers BK; Fitts K; Whalum K; Whalum K; Hemphill AD; Manikonda J; Martinez LM; Riley EG; Roof CM; Sarwar N; Thomas DM; Ulmer E; Wallace FE; Pandey P; Roy S
    Viruses; 2020 Aug; 12(9):. PubMed ID: 32859008
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Targeting two potential sites of SARS-CoV-2 main protease through computational drug repurposing.
    Prakash A; Borkotoky S; Dubey VK
    J Biomol Struct Dyn; 2023 Apr; 41(7):3014-3024. PubMed ID: 35266856
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Molecular Docking and Dynamics Investigations for Identifying Potential Inhibitors of the 3-Chymotrypsin-like Protease of SARS-CoV-2: Repurposing of Approved Pyrimidonic Pharmaceuticals for COVID-19 Treatment.
    Elzupir AO
    Molecules; 2021 Dec; 26(24):. PubMed ID: 34946540
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Identify potent SARS-CoV-2 main protease inhibitors via accelerated free energy perturbation-based virtual screening of existing drugs.
    Li Z; Li X; Huang YY; Wu Y; Liu R; Zhou L; Lin Y; Wu D; Zhang L; Liu H; Xu X; Yu K; Zhang Y; Cui J; Zhan CG; Wang X; Luo HB
    Proc Natl Acad Sci U S A; 2020 Nov; 117(44):27381-27387. PubMed ID: 33051297
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ensemble-based screening of natural products and FDA-approved drugs identified potent inhibitors of SARS-CoV-2 that work with two distinct mechanisms.
    Shadrack DM; Deogratias G; Kiruri LW; Swai HS; Vianney JM; Nyandoro SS
    J Mol Graph Model; 2021 Jun; 105():107871. PubMed ID: 33684603
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Repurposing drugs for treatment of SARS-CoV-2 infection: computational design insights into mechanisms of action.
    Kandwal S; Fayne D
    J Biomol Struct Dyn; 2022 Feb; 40(3):1316-1330. PubMed ID: 32964805
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Identifying SARS-CoV-2 Drugs Binding to the Spike Fatty Acid Binding Pocket Using In Silico Docking and Molecular Dynamics.
    Piplani S; Singh P; Petrovsky N; Winkler DA
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835602
    [TBL] [Abstract][Full Text] [Related]  

  • 48.
    Mateev E; Georgieva M; Zlatkov A
    Comb Chem High Throughput Screen; 2023; 26(6):1242-1250. PubMed ID: 35984023
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity.
    Tsuji M
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232311
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Profiling SARS-CoV-2 Main Protease (M
    Gupta A; Zhou HX
    ACS Comb Sci; 2020 Dec; 22(12):826-832. PubMed ID: 33119257
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Target identification for repurposed drugs active against SARS-CoV-2 via high-throughput inverse docking.
    Ribone SR; Paz SA; Abrams CF; Villarreal MA
    J Comput Aided Mol Des; 2022 Jan; 36(1):25-37. PubMed ID: 34825285
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Venetoclax: a promising repurposed drug against SARS-CoV-2 main protease.
    Ghosh S; Bhattacherjee D; Satpati P; Bhabak KP
    J Biomol Struct Dyn; 2022; 40(22):12088-12099. PubMed ID: 34424151
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Searching for potential drugs against SARS-CoV-2 through virtual screening on several molecular targets.
    Almeida JSFD; Botelho FD; de Souza FR; Dos Santos MC; Goncalves ADS; Rodrigues RLB; Cardozo M; Kitagawa DAS; Vieira LA; Silva RSF; Cavalcante SFA; Bastos LDC; Nogueira MOT; de Santana PIR; Brum JOC; Nepovimova E; Kuca K; LaPlante SR; Galante EBF; Franca TCC
    J Biomol Struct Dyn; 2022 Jul; 40(11):5229-5242. PubMed ID: 33416020
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Plant derived active compounds as potential anti SARS-CoV-2 agents: an
    Kashyap D; Jakhmola S; Tiwari D; Kumar R; Moorthy NSHN; Elangovan M; Brás NF; Jha HC
    J Biomol Struct Dyn; 2022; 40(21):10629-10650. PubMed ID: 34225565
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The anti-HCV, Sofosbuvir, versus the anti-EBOV Remdesivir against SARS-CoV-2 RNA dependent RNA polymerase in silico.
    Elfiky AA; Azzam EB; Shafaa MW
    Mol Divers; 2022 Feb; 26(1):171-181. PubMed ID: 33389441
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Computational drug repurposing study of the RNA binding domain of SARS-CoV-2 nucleocapsid protein with antiviral agents.
    Tatar G; Ozyurt E; Turhan K
    Biotechnol Prog; 2021 Mar; 37(2):e3110. PubMed ID: 33314794
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Identifying non-nucleoside inhibitors of RNA-dependent RNA-polymerase of SARS-CoV-2 through per-residue energy decomposition-based pharmacophore modeling, molecular docking, and molecular dynamics simulation.
    Aziz S; Waqas M; Mohanta TK; Halim SA; Iqbal A; Ali A; Khalid A; Abdalla AN; Khan A; Al-Harrasi A
    J Infect Public Health; 2023 Apr; 16(4):501-519. PubMed ID: 36801630
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Synthetic flavonoids as potential antiviral agents against SARS-CoV-2 main protease.
    Batool F; Mughal EU; Zia K; Sadiq A; Naeem N; Javid A; Ul-Haq Z; Saeed M
    J Biomol Struct Dyn; 2022 May; 40(8):3777-3788. PubMed ID: 33251983
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Repurposing of potential antiviral drugs against RNA-dependent RNA polymerase of SARS-CoV-2 by computational approach.
    Gangadharan S; Ambrose JM; Rajajagadeesan A; Kullappan M; Patil S; Gandhamaneni SH; Veeraraghavan VP; Nakkella AK; Agarwal A; Jayaraman S; Surapaneni KM
    J Infect Public Health; 2022 Nov; 15(11):1180-1191. PubMed ID: 36240528
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Virtual high throughput screening: Potential inhibitors for SARS-CoV-2 PL
    Jade D; Ayyamperumal S; Tallapaneni V; Joghee Nanjan CM; Barge S; Mohan S; Nanjan MJ
    Eur J Pharmacol; 2021 Jun; 901():174082. PubMed ID: 33823185
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.